PARP inhibition and pharmacological ascorbate demonstrate synergy in castration-resistant prostate cancer.

Nicolas GordonPeter T GallagherNeermala Poudel NeupaneAmy C MandigoJennifer K McCannEmanuela DylgjeriIrina VasilevskayaChristopher McNairChanning J PallerWm Kevin KellyKaren E KnudsenAyesha A ShafiMatthew J Schiewer

Published in: bioRxiv : the preprint server for biology (2023)

. These findings nominate ascorbate and PARPi as a novel therapeutic regimen that has the potential to improve CRPC patient outcomes.

Keyphrases

dna damage
dna repair
risk assessment